Brief Description

CERC-501 (formerly known as LY-2456302) is a selective, short-acting antagonist of the κ-opioid receptor (Ki = 0.81 nM vs. 24.0 nM and 155 nM for the μ- and δ-opioid receptors, respectively). The molecule is being developed as a psychiatric drug by Cerecor Inc. of Baltimore.
It was originally developed by Eli Lily as an augmentation to antidepressant therapy for treatment-resistant depression, under the name LY-2456302, and was under phase II clinical trials in the United States. In animal models of depression, CERC-501 has been found to have potent synergistic efficacy in combination with other antidepressants such as citalopram and imipramine.
In February 2015, Cerecor Inc. announced that they have acquired the rights to develop and commercialize the molecule.
From: http://en.wikipedia.org/wiki/CERC-501

Solubility

DMSO

Melting point

Boiling point

Density

Formula Weight:

Flash point

Storage conditions

Store at -20°C 2 years

Appearance: